[Two new therapeutic principles in the management of breast cancer and colorectal cancer: selective oral aromatase inhibition and thymidilate synthase inhibition].
D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009570:Nitriles / Q000627:therapeutic use*; D010166:Palliative Care; D014230:Triazoles / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole
Zwei neue Therapieprinzipien bei Mammakarzinom und kolorektalen Karzinomen: Selektive orale Aromatasehemmung und Thymidilatsynthase-inhibition.